The first generic carfilzomib for injection of Hausen Pharmaceuticals was approved for only two months after the original research report

On September 7, CDE's official website showed that Hausen Pharmaceuticals' application for carfilzomib for injection was accepted and accepted

From: CDE official website

Carfilzomib (carfilzomib) is a proteasome inhibitor, approved by the FDA on July 20, 2012, for patients with multiple myeloma who have received at least two previous types (bortezomib and immunomodulators).

The drug's rights have changed hands several times: it was originally developed by Proteolix.

In November 2019, BeiGene and Amgen reached a cooperation to develop and commercialize Amgen's many products in China, one of which is Carfilzomi (KYPROLIS®)

Proteasome inhibitors are the first line of choice for multiple myeloma.

In a phase III study code-named ENDEAVOR, the results of an overall survival (OS) interim analysis according to a predetermined plan showed that Kyprolis (carfilzomib) + dexamethasone treats patients with relapsed or refractory multiple myeloma Compared with Velcade (bortezomib) + dexamethasone, the median OS can be prolonged by 7.

Since its listing, Carfilzomi's sales have continued to grow

Image source: Insight database (https://db.

Insight database shows that at present, no carfilzomib product has been approved for listing in China except for the original research

At present, in addition to Hausen, there are five other companies deploying carfilzomi generic drugs, all of which are currently in the clinical approval stage

Details of competition of carfilzomib for injection

Image source: Insight database (https://db.